该药物属于法尼酯 X 受体(Farnesoid X receptor，FXR)激动剂。FXR 是一种在肝脏和肠道中高水平表达的核受体，在胆酸代谢调节中起关键性作用。该药物是 ...
GlobalData on MSN4 天
Advanz Pharma’s liver disease drug pulled from European market after court hearingThis latest update comes after Advanz secured a suspension of the European Commission’s original revocation in September 2024 ...
The Swiss pharma said it is to begin a phase IIb trial of one of its Farnesoid X receptor (FXR) agonists in combination with Allergan’s cenicriviroc in NASH. A group of around half a dozen ...
Medpage Today on MSN3 天
Expanded Treatment Options for Primary Biliary Cholangitis Leave Open QuestionsThe approval of ursodeoxycholic acid (UDCA) for primary biliary cholangitis (PBC) in 1997 marked a pivotal turning point in ...
GlobalData on MSN1 个月
Intercept’s liver disease drug Ocaliva faces FDA approval delayOcaliva activates the farnesoid X receptor (FXR) to reduce bile acid production and promote its removal. Ocaliva now faces ...
GlobalData on MSN18 天
Intercept loses Ocaliva FDA full approval bid in rare liver diseaseIntercept’s US president Vivek Devaraj said the pharma company still believes in the evidence supporting the liver disease ...
during which a panel of outside experts nearly unanimously voted against Intercept’s request for a full approval of its farnesoid X receptor agonist. During the meeting, 13 of the FDA’s ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈